Menu
PRESS RELEASES
REPORTS
We are developing the next-generation treatment system for prostate cancer
SpectraCure is a medical technology company focused on developing a new treatment system for localised prostate cancer. Our goal is to offer a highly precise focal treatment, which has the potential to provide a more individualised and minimally invasive solution for prostate cancer. In the future the treatment system has the potential to be adapted for other types of internal solid tumours such as cancer in the breast, pancreas and in the head and neck region.
A clinical trial for patients experiencing recurrent prostate cancer is underway, at leading prostate cancer clinics in North America and Europe. Additionally, we are in the process of initiating another clinical trial, for patients with primary localised prostate cancer.
SpectraCure utilies PDT for the treatment of solid internal tumours
Purpose
We are confident that
the combination of medical technology and ground-breaking research has the potential to change cancer treatment.
Mission
We want to change the landscape of cancer treatments. By combining the proven method PDT with advanced technology, our goal is to effectively treat cancer tumours in the future.
What we do
We are developing the medical technology systems of the future, which have the potential to offer an individualised cancer treatment, with few side effects.
“…SpectraCure represents the future of personalized PDT in prostate cancer treatment…”
Brian Wilson, Senior Scientist at Princess Margaret Cancer Center and professor at the University of Toronto, Department of Medical Biophysics.
Prostate cancer is a significant health challenge. Approximately 13% of all men are expected to be diagnosed with prostate cancer in their lifetime. The current treatments for prostate cancer present multifaceted challenges, often accompanied by significant side effects like urinary incontinence and sexual dysfunction, which can greatly impact patients’ quality of life. Given the complexity of prostate cancer, there is a pressing need for individualised, focal, and cost-effective treatment options. SpectraCure aims to contribute to be a part of the solution!
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.